These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25720990)

  • 1. The RANKL-RANK Story.
    Nagy V; Penninger JM
    Gerontology; 2015; 61(6):534-42. PubMed ID: 25720990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL/RANK - from bone physiology to breast cancer.
    Sigl V; Penninger JM
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
    Schramek D; Sigl V; Penninger JM
    Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
    Delmas PD
    J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.
    Woźniczka M; Błaszczak-Świątkiewicz K
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
    Kearns AE; Khosla S; Kostenuik PJ
    Endocr Rev; 2008 Apr; 29(2):155-92. PubMed ID: 18057140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis and aterosclerosis--is there any pathogenetic association?].
    Zofková I
    Cas Lek Cesk; 2007; 146(3):246-50. PubMed ID: 17419308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Central regulation of body temperature by RANKL/RANK pathway].
    Hanada R; Penninger JM
    Clin Calcium; 2011 Aug; 21(8):1201-8. PubMed ID: 21814026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK/RANKL: regulators of immune responses and bone physiology.
    Leibbrandt A; Penninger JM
    Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.